Talazoparib and enzalutamide for advanced prostate cancer after prior treatment
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of two drugs, talazoparib and enzalutamide, in men with advanced prostate cancer that has progressed after previous treatment with a hormone therapy called an AR inhibitor. It aims to see if this combination can help control the cancer and delay further progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older.
- You have been diagnosed with adenocarcinoma of the prostate (a common type of prostate cancer) that has spread to other parts of the body.
- Your cancer has worsened while on a previous AR inhibitor (such as enzalutamide, apalutamide, or darolutamide) after at least 12 weeks of treatment.
- You are able to perform daily activities with minimal help (ECOG performance status 0 or 1).
- You are willing to provide tumor biopsies (both fresh and archived) and blood samples for research.
- You have adequate organ function, as confirmed by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests several new drug combinations for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to find better ways to control the disease and improve outcomes.
This study tests a drug called talazoparib, either alone or combined with enzalutamide, in people with prostate cancer that has spread and has a specific genetic change. The goal is to see if this treatment can help control the cancer after previous therapies have stopped working.
This expanded access program provides the experimental drug talazoparib (given in combination with enzalutamide) to patients with newly diagnosed metastatic prostate cancer that has become castrate-resistant (no longer responding to hormone therapy). The goal is to make this treatment available before it is formally approved.
This trial studies whether taking talazoparib and enzalutamide before surgery can shrink or control prostate cancer. If treatment works, it may make the cancer easier to remove with a radical prostatectomy.
This trial tests whether talazoparib added to standard hormone therapy (ADT), along with abiraterone, can better control metastatic prostate cancer that hasn’t progressed despite starting hormone treatment. It may help people live longer and delay cancer worsening.
This Phase 2 trial tests whether giving testosterone first, then enzalutamide (a prostate cancer hormone-blocking pill), can slow or prevent worsening metastatic prostate cancer. It is designed for men whose cancer progressed despite ongoing hormone-suppression treatment.
Hear when a new Metastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.